Drug Trial Radar · NCT00571727
Long-Term Treatment With rhIGF-1 in GHIS
Last checked: Nov 20, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
May 20, 1991
Primary completion
Dec 15, 2011
Study completion Dec 15, 2011
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- Collaborators
- University of Oklahoma
- First posted
- Dec 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).
Conditions
- Growth Hormone Insensitivity Syndrome
Interventions
mecaserminDrug
injections BID of rhIGF-1, mecasermin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Height Velocity Up to 12 YearsTime frame: Baseline (Pre-dose) and up to 12 years
- Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year of Study TreatmentTime frame: Baseline (Pre-dose) and 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ipsen
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.